← Back to Screener
Bon Natural Life Limited Class A Ordinary Shares (BON)
Price$1.34
Favorite Metrics
Price vs S&P 500 (26W)-46.84%
Price vs S&P 500 (4W)-18.58%
Market Capitalization$10.57M
All Metrics
P/CF (Annual)74.88x
Book Value / Share (Quarterly)$7.08
P/TBV (Annual)0.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-14.54%
Cash Flow / Share (Quarterly)$-1.21
Price vs S&P 500 (YTD)-22.38%
Gross Margin (TTM)20.77%
Net Profit Margin (TTM)-10.68%
EPS (TTM)$0.09
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$0.09
Revenue Growth (5Y)0.49%
EPS (Annual)$-0.72
ROI (Annual)-2.86%
Gross Margin (Annual)20.77%
Net Profit Margin (5Y Avg)9.08%
Cash / Share (Quarterly)$0.46
Revenue Growth QoQ (YoY)-21.52%
ROA (Last FY)-2.34%
Revenue Growth TTM (YoY)-21.70%
EBITD / Share (TTM)$-0.09
ROE (5Y Avg)9.83%
Operating Margin (TTM)-8.69%
Cash Flow / Share (Annual)$-1.21
P/B Ratio0.18x
P/B Ratio (Quarterly)0.21x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.02x
Net Interest Coverage (TTM)-3.68x
ROA (TTM)-2.54%
EV / EBITDA (TTM)8.39x
EPS Incl Extra (Annual)$-0.72
Current Ratio (Annual)1.74x
Quick Ratio (Quarterly)1.28x
3-Month Avg Trading Volume0.05M
52-Week Price Return-5.11%
EV / Free Cash Flow (Annual)5.38x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.29
P/S Ratio (Annual)0.57x
Asset Turnover (Annual)0.22x
52-Week High$3.40
Operating Margin (5Y Avg)12.45%
EPS Excl Extra (Annual)$-0.72
CapEx CAGR (5Y)18.20%
26-Week Price Return-38.10%
Quick Ratio (Annual)1.28x
13-Week Price Return-25.29%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)1.74x
Enterprise Value$18.974
Revenue / Share Growth (5Y)-21.53%
Asset Turnover (TTM)0.24x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)6.07x
Pretax Margin (Annual)-9.16%
Cash / Share (Annual)$0.46
3-Month Return Std Dev33.08%
Gross Margin (5Y Avg)27.99%
Net Income / Employee (TTM)$-0
ROE (Last FY)-3.47%
Net Interest Coverage (Annual)-3.68x
EPS Basic Excl Extra (Annual)$-0.72
P/FCF (TTM)29.94x
Receivables Turnover (TTM)1.64x
EV / Free Cash Flow (TTM)1.87x
Total Debt / Equity (Quarterly)0.21x
EPS Incl Extra (TTM)$0.09
Receivables Turnover (Annual)1.64x
ROI (TTM)-3.02%
P/S Ratio (TTM)0.57x
Pretax Margin (5Y Avg)11.81%
Revenue / Share (Annual)$6.78
Tangible BV / Share (Annual)$6.29
Price vs S&P 500 (52W)-40.20%
EPS Growth TTM (YoY)-96.73%
Year-to-Date Return-18.24%
5-Day Price Return0.78%
EPS Normalized (Annual)$-0.72
ROA (5Y Avg)7.50%
Net Profit Margin (Annual)-10.68%
Month-to-Date Return0.78%
Cash Flow / Share (TTM)$0.71
EBITD / Share (Annual)$-0.09
Operating Margin (Annual)-8.69%
LT Debt / Equity (Annual)0.01x
P/CF (TTM)74.88x
ROI (5Y Avg)8.74%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$0.09
P/TBV (Quarterly)0.24x
P/B Ratio (Annual)0.21x
Inventory Turnover (TTM)6.07x
Pretax Margin (TTM)-9.16%
Book Value / Share (Annual)$7.08
Price vs S&P 500 (13W)-28.15%
Beta-0.15x
P/FCF (Annual)353.43x
Revenue / Share (TTM)$3.59
ROE (TTM)-3.59%
52-Week Low$1.13
Industry Peers — Pharmaceutical Preparations(15)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BONBon Natural Life Limited Class A Ordinary Shares | 0.57x | -21.70% | 20.77% | — | $1.34 |
CRONCronos Group Inc. Common Share | 6.99x | 24.63% | 42.81% | -49.98% | $2.76 |
TLRYTilray Brands, Inc. Common Stock | 0.97x | 3.82% | 27.68% | — | $7.15 |
CGCCanopy Growth Corporation Common Shares | 2.55x | 0.59% | 26.56% | — | $1.20 |
NAGENiagen Bioscience, Inc. Common Stock | 3.01x | 29.95% | 64.28% | — | $4.87 |
USNAUSANA Health Sciences Inc | 0.41x | 5.88% | 78.29% | -37.04% | $20.64 |
SNDLSundial Growers Inc. Common Shares | 0.58x | 2.82% | 27.33% | — | $1.54 |
MDWDMediWound Ltd. | 13.35x | -16.14% | 19.19% | — | $17.35 |
ACBAurora Cannabis Inc. Common Shares | 0.77x | 16.54% | 1.35% | — | $3.72 |
BTMDBiote Corp. Class A Common Stock | 0.46x | -2.52% | 71.46% | -26.84% | $2.24 |
FTLFFitLife Brands, Inc. Common Stock | 1.29x | 1.34% | 37.58% | -20.04% | $8.99 |
About
Bon Natural Life Ltd manufactures natural personal care and health ingredients, primarily plant-extracted fragrance compounds for cosmetic applications, along with natural health supplements and bioactive food ingredients. The company has developed proprietary technology platforms for extraction, safety enhancement, and functional compounding of natural products. Revenue is primarily derived from fragrance compound sales to perfume and cosmetic manufacturers, with additional revenue from supplement and food ingredient customers.